Literature DB >> 21233420

VHL loss in renal cell carcinoma leads to up-regulation of CUB domain-containing protein 1 to stimulate PKC{delta}-driven migration.

Olga V Razorenova1, Elizabeth C Finger, Renata Colavitti, Sophia B Chernikova, Alexander D Boiko, Charles K F Chan, Adam Krieg, Barbara Bedogni, Edward LaGory, Irving L Weissman, Marianne Broome-Powell, Amato J Giaccia.   

Abstract

A common genetic mutation found in clear cell renal cell carcinoma (CC-RCC) is the loss of the von Hippel-Lindau (VHL) gene, which results in stabilization of hypoxia-inducible factors (HIFs), and contributes to cancer progression and metastasis. CUB-domain-containing protein 1 (CDCP1) was shown to promote metastasis in scirrhous and lung adenocarcinomas as well as in prostate cancer. In this study, we established a molecular mechanism linking VHL loss to induction of the CDCP1 gene through the HIF-1/2 pathway in renal cancer. Also, we report that Fyn, which forms a complex with CDCP1 and mediates its signaling to PKCδ, is a HIF-1 target gene. Mechanistically, we found that CDCP1 specifically regulates phosphorylation of PKCδ, but not of focal adhesion kinase or Crk-associated substrate. Signal transduction from CDCP1 to PKCδ leads to its activation, increasing migration of CC-RCC. Furthermore, patient survival can be stratified by CDCP1 expression at the cell surface of the tumor. Taken together, our data indicates that CDCP1 protein might serve as a therapeutic target for CC-RCC.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21233420      PMCID: PMC3033256          DOI: 10.1073/pnas.1011777108

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  41 in total

Review 1.  HIF-1 as a target for drug development.

Authors:  Amato Giaccia; Bronwyn G Siim; Randall S Johnson
Journal:  Nat Rev Drug Discov       Date:  2003-10       Impact factor: 84.694

2.  Increased protein kinase C delta in mammary tumor cells: relationship to transformtion and metastatic progression.

Authors:  S C Kiley; K J Clark; S K Duddy; D R Welch; S Jaken
Journal:  Oncogene       Date:  1999-11-18       Impact factor: 9.867

3.  Subtractive immunization using highly metastatic human tumor cells identifies SIMA135/CDCP1, a 135 kDa cell surface phosphorylated glycoprotein antigen.

Authors:  John D Hooper; Andries Zijlstra; Ronald T Aimes; Hongyan Liang; Gisela F Claassen; David Tarin; Jacqueline E Testa; James P Quigley
Journal:  Oncogene       Date:  2003-03-27       Impact factor: 9.867

4.  Phosphorylation sites of protein kinase C delta in H2O2-treated cells and its activation by tyrosine kinase in vitro.

Authors:  H Konishi; E Yamauchi; H Taniguchi; T Yamamoto; H Matsuzaki; Y Takemura; K Ohmae; U Kikkawa; Y Nishizuka
Journal:  Proc Natl Acad Sci U S A       Date:  2001-05-29       Impact factor: 11.205

5.  Altered protein kinase C (PKC) isoforms in non-small cell lung cancer cells: PKCdelta promotes cellular survival and chemotherapeutic resistance.

Authors:  Amy S Clark; Kip A West; Peter M Blumberg; Phillip A Dennis
Journal:  Cancer Res       Date:  2003-02-15       Impact factor: 12.701

6.  FGF-2 and TPA induce matrix metalloproteinase-9 secretion in MCF-7 cells through PKC activation of the Ras/ERK pathway.

Authors:  Jian-Feng Liu; Michel Crépin; Jian-Miao Liu; Denis Barritault; Dominique Ledoux
Journal:  Biochem Biophys Res Commun       Date:  2002-05-17       Impact factor: 3.575

7.  Hypoxia-induced lysyl oxidase is a critical mediator of bone marrow cell recruitment to form the premetastatic niche.

Authors:  Janine T Erler; Kevin L Bennewith; Thomas R Cox; Georgina Lang; Demelza Bird; Albert Koong; Quynh-Thu Le; Amato J Giaccia
Journal:  Cancer Cell       Date:  2009-01-06       Impact factor: 31.743

Review 8.  Targeting HIF-1 for cancer therapy.

Authors:  Gregg L Semenza
Journal:  Nat Rev Cancer       Date:  2003-10       Impact factor: 60.716

9.  Protein kinase C delta is a prosurvival factor in human breast tumor cell lines.

Authors:  Meredith A McCracken; Loren J Miraglia; Robert A McKay; Jeannine S Strobl
Journal:  Mol Cancer Ther       Date:  2003-03       Impact factor: 6.261

10.  Differential roles of hypoxia-inducible factor 1alpha (HIF-1alpha) and HIF-2alpha in hypoxic gene regulation.

Authors:  Cheng-Jun Hu; Li-Yi Wang; Lewis A Chodosh; Brian Keith; M Celeste Simon
Journal:  Mol Cell Biol       Date:  2003-12       Impact factor: 4.272

View more
  47 in total

1.  CDCP1 cleavage is necessary for homodimerization-induced migration of triple-negative breast cancer.

Authors:  H J Wright; J Arulmoli; M Motazedi; L J Nelson; F S Heinemann; L A Flanagan; O V Razorenova
Journal:  Oncogene       Date:  2016-02-15       Impact factor: 9.867

2.  The cell surface glycoprotein CUB domain-containing protein 1 (CDCP1) contributes to epidermal growth factor receptor-mediated cell migration.

Authors:  Ying Dong; Yaowu He; Leonore de Boer; M Sharon Stack; John W Lumley; Judith A Clements; John D Hooper
Journal:  J Biol Chem       Date:  2012-02-07       Impact factor: 5.157

3.  CDCP1 drives triple-negative breast cancer metastasis through reduction of lipid-droplet abundance and stimulation of fatty acid oxidation.

Authors:  Heather J Wright; Jue Hou; Binzhi Xu; Marvin Cortez; Eric O Potma; Bruce J Tromberg; Olga V Razorenova
Journal:  Proc Natl Acad Sci U S A       Date:  2017-07-24       Impact factor: 11.205

Review 4.  Hypoxia, Hypoxia-inducible Transcription Factors, and Renal Cancer.

Authors:  Johannes Schödel; Steffen Grampp; Eamonn R Maher; Holger Moch; Peter J Ratcliffe; Paul Russo; David R Mole
Journal:  Eur Urol       Date:  2015-08-19       Impact factor: 20.096

5.  Targeting CDCP1 dimerization in triple-negative breast cancer.

Authors:  Heather J Wright; Alice M Police; Olga V Razorenova
Journal:  Cell Cycle       Date:  2016-06-30       Impact factor: 4.534

6.  Regulation of inside-out β1-integrin activation by CDCP1.

Authors:  Sara G Pollan; Fangjin Huang; Jamie M Sperger; Joshua M Lang; Colm Morrissey; Anne E Cress; C Y Chu; Neil A Bhowmick; Sungyong You; Michael R Freeman; Danislav S Spassov; Mark M Moasser; William G Carter; Shakti Ranjan Satapathy; Kavita Shah; Beatrice S Knudsen
Journal:  Oncogene       Date:  2018-03-07       Impact factor: 9.867

Review 7.  Protein kinase C and cancer: what we know and what we do not.

Authors:  R Garg; L G Benedetti; M B Abera; H Wang; M Abba; M G Kazanietz
Journal:  Oncogene       Date:  2013-12-16       Impact factor: 9.867

8.  Src Kinase Is Biphosphorylated at Y416/Y527 and Activates the CUB-Domain Containing Protein 1/Protein Kinase C δ Pathway in a Subset of Triple-Negative Breast Cancers.

Authors:  Luke J Nelson; Heather J Wright; Nguyen B Dinh; Kevin D Nguyen; Olga V Razorenova; F Scott Heinemann
Journal:  Am J Pathol       Date:  2019-12-13       Impact factor: 4.307

9.  Identification of CDCP1 as a hypoxia-inducible factor 2α (HIF-2α) target gene that is associated with survival in clear cell renal cell carcinoma patients.

Authors:  Brooke M Emerling; Cyril H Benes; George Poulogiannis; Eric L Bell; Kevin Courtney; Hui Liu; Rayman Choo-Wing; Gary Bellinger; Kazumi S Tsukazawa; Victoria Brown; Sabina Signoretti; Stephen P Soltoff; Lewis C Cantley
Journal:  Proc Natl Acad Sci U S A       Date:  2013-02-01       Impact factor: 11.205

10.  In vivo cleaved CDCP1 promotes early tumor dissemination via complexing with activated β1 integrin and induction of FAK/PI3K/Akt motility signaling.

Authors:  B Casar; I Rimann; H Kato; S J Shattil; J P Quigley; E I Deryugina
Journal:  Oncogene       Date:  2012-12-03       Impact factor: 9.867

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.